These findings suggest that developing pharmacological treatments aimed at either maintaining or increasing SOX18 expression could be useful for treating patients with VILI and with sepsis-induced ARDS that are treated with mechanical ventilation. This evidence concerns the gene SOX18 and acute respiratory distress syndrome.